Next-generation sequencing (NGS) is becoming a critical component of molecular testing in both myeloid and lymphoproliferative neoplasms. During this webinar, hear from experts on the latest advances in the application of fast NGS for myeloid genomic profiling and myeloid measurable residual disease (MRD). The presentations will feature our NGS testing solutions, which offers a fully complete workflow capable of delivering results in just 1-3 days. See how these groundbreaking testing methods are helping to advance research in Hemato-oncology care.

Key Learning Objectives:

  1. Learn about the recent implementation of rapid NGS in the research laboratory for genomic profiling of Hematological malignancies and the user experience with Oncomine Myeloid assay.
  2. Understand how Next Generation Sequencing can address key challenges with the molecular analysis of Acute Myeloid Leukemia and other related hematological malignancies.
  3. Find out how Thermo Fisher Scientific Oncomine Measurable Residual Disease assay can play a role in disease monitoring.

 

Duration90 minutes
LanguageEnglish
TypeOn-demand

Watch on-demand

For Research Use Only.  Not for use on diagnostic procedures.
©2023 Thermo Fisher Scientific Inc.  All rights reserved.  All trademarks are the property of Thermo Fisher Scientific and its subsidiaries, unless otherwise specified.